23754-45-2

Basic information

• Product Name: 4-[(Methylamino)carbonyl]benzoic acid
• Synonyms: 4-[(Methylamino)carbonyl]benzoic acid
• CAS NO: 23754-45-2
• Molecular Formula: C₉H₉NO₃
• Molecular Weight: 179.17266
• Mol File: 23754-45-2.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-[(Methylamino)carbonyl]benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(Methylamino)carbonyl]benzoic acid(23754-45-2)
• EPA Substance Registry System: 4-[(Methylamino)carbonyl]benzoic acid(23754-45-2)

Safety Data

• Hazard Codes: Xi
• Statements: 43
• Safety Statements: 36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 23754-45-2(Hazardous Substances Data)

Upstream product

• 1679-64-7 Monomethyl terephthalate 
• 7377-26-6 4-Methoxycarbonylbenzoyl chloride 
• 18370-11-1 N-methyl-p-methylbenzamide 
• 99-94-5 p-Toluic acid 
• 79-37-8 oxalyl dichloride 
• 23754-46-3 methyl 4-(methylaminocarbonyl)benzoate 

Downstream Products

• 1251164-23-4 N-methyl-4-[(7-quinolin-3-yl-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl)carbonyl]benzamide 
• 1091610-32-0 C₂₇H₃₂N₆O₄ 

Relevant articles and documents

Ring size changes in the development of class I HDAC inhibitors

Five pathways involving different ring structures led to generation of fourteen thienylbenzamides (7–20) which display the structure-activity relationships of class I HDAC inhibitors. All the synthesised compounds inhibit HDAC1 and HDAC2 selectively over other isoforms and many inhibit DLD1 and HCT116 cells more effectively than a parent compound. Compounds 8 and 16 inhibit HCT116 cells by activation of the apoptosis pathway.

Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions

Aminopeptidase N (APN/CD13) is a zinc-dependent M1 aminopeptidase that contributes to cancer progression by promoting angiogenesis, metastasis, and tumor invasion. We have previously identified hydroxamic acid-containing analogues that are potent inhibitors of the APN homologue from the malarial parasite Plasmodium falciparum M1 aminopeptidase (PfA-M1). Herein, we describe the rationale that underpins the repurposing of PfA-M1 inhibitors as novel APN inhibitors. A series of novel hydroxamic acid analogues were developed using a structure-based design approach and evaluated their inhibition activities against APN. N-(2-(Hydroxyamino)-2-oxo-1-(3′,4′,5′-trifluoro-[1,1′-biphenyl]-4-yl)ethyl)-4-(methylsulfonamido)benzamide (6ad) proved to be an extremely potent inhibitor of APN activity in vitro, selective against other zinc-dependent enzymes such as matrix metalloproteases, and possessed limited cytotoxicity against Ad293 cells and favorable physicochemical and metabolic stability properties. The combined results indicate that compound 6ad may be a useful lead for the development of anticancer agents.

Design of novel CSA analogues as potential safeners and fungicides

Study of safeners has been seldom reported in literature. In this work, a series of novel acylsulfamoylbenzamide analogues was designed and synthesized with newly developed safener cyprosulfamide (CSA) as the leading compound. The activity assay against the herbicide thiencarbazone-methyl (TCM) on maize revealed that fifteen compounds showed better protective effect than CSA on the fresh weight of aerial parts, twelve compounds exhibited better activity on the dry weight of aerial parts. Remarkably, two compounds (6Ih, 7II) had protective effect on the four aspects of TCM treated maize. Further antifungal assay showed their excellent activity against Physollospora piricola. The structure-activity relationships of CSA analogues as safeners and fungicides were discussed and it might be valuable for further molecular modification of new CSA analogues.